<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04257721</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A01495-52</org_study_id>
    <nct_id>NCT04257721</nct_id>
  </id_info>
  <brief_title>Predictive Score For Maxillary Osteonecrosis After Invasive Oral Surgery</brief_title>
  <acronym>PREV-ONM</acronym>
  <official_title>Development Of A Predictive Score For Maxillary Osteochimionecrosis After Invasive Oral Surgery In Patients Treated Whith Biphosphonates Or Biotherapies: The PREV-ONM Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Sud Francilien</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Sud Francilien</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-interventional prospective multicentre cohort study to determine a predictive score for
      the occurrence of osteochimionecrosis of the jaws after invasive oral surgery in patients who
      have received biphosphonates or antangiogenic drugs as part of chemotherapy with malignant
      bone disease (multiple myeloma or bone metastasis of a solid tumour).

      Data are collected during the usual follow-up of patients during the first 3 months following
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-interventional prospective multicentre cohort study to determine a predictive score for
      the occurrence of osteochimionecrosis of the jaws after invasive oral surgery in patients who
      have received at least one of the following molecules as part of chemotherapy with malignant
      bone disease (multiple myeloma or bone metastasis of a solid tumour):

        -  Biphosphonates: ZOLEDRONATE (ZOMETA®), PAMIDRONATE (AREDIA®, OSTEPAM®)

        -  Anti-angiogenic: DENOSUMAB (XGEVA®), BEVACIZUMAB (AVASTIN®), RITUXIMAB (MABTHERA®,
           RIXATHON®, TRUXIMA®), SUNITINIB (SUTENT®), PAZOPANIB (VOTRIENT®), AXITINIB (INLYTA®),
           CARBOZANTINIB (CABOMETYX®, COMETRIQ®), SORAFENIB (NEXAVAR®)

      The study protocol is based on the post-operative clinical and radiographic follow-up of
      patients. 3 consultations are scheduled:

        -  1 week after surgery

        -  1 month after surgery

        -  3 months after surgery

      The following information should be noted at each follow-up consultation:

        -  Appearance of gingival and mucosal tissues : normal or inflammatory physiological state

        -  Description of possible bone exposure: size, colour, spontaneous or induced bleeding

        -  Description and assessment of local pain

        -  Description of a local infection

        -  Results of a bacteriological sample in case of suppuration

      The patient's participation in the study ends:

        -  at the end of one of the consultations at 1 week and 1 month as soon as
           osteochimionecrosis of the jaws is diagnosed by the investigating physician

        -  at the end of the consultation at 3 months otherwise

        -  in the event of the patient's death during the study

        -  in the event of the patient's renouncement to participate in the study The patient's
           participation period is therefore a maximum of 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2019</start_date>
  <completion_date type="Anticipated">January 6, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 6, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>occurrence of osteonecrosis of the jaw</measure>
    <time_frame>within 3 months after surgery</time_frame>
    <description>occurrence of osteonecrosis of the jaw</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of post-operative healing (bone and gingival) and comparison to each patient's UCONNS score.</measure>
    <time_frame>within 3 months after surgery</time_frame>
    <description>Frequency of post-operative healing (bone and gingival) and comparison to each patient's UCONNS score.
The UCONNS score was proposed in 2011. Its objective is to be able to predict the occurrence of osteochimionecrosis in conjunction with biphosphonate treatment before a dental invasive procedure (dental avulsions, implant placement, etc.). It takes into account several types of variables:
The patient's general condition and comorbidities (HIV, osteoporosis, rheumatoid arthritis, diabetes, presence or not of a soft tissue tumour, presence or not of a breast or prostate tumour, multiple myeloma, ...)
The nature, dose, and duration of use of the biphosphonate received
Oral hygiene
presence of suppuration, presence of osteomyelitis
The dental surgery received (endodontic treatment, periodontal treatment, surgery muco-gingival, tooth extraction, apical surgery, bone resection)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Osteonecrosis Due to Drugs, Jaw</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients who have received biphosphonates or antangiogenic drugs as part of chemotherapy
        with malignant bone disease (multiple myeloma or bone metastasis of a solid tumour) and who
        has had an oral surgical procedure (single or multiple dental extraction, with or without
        alveolectomy, under local or general anesthesia)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who have received at least one of the following molecules as part of
             chemotherapy with malignant bone disease (multiple myeloma or bone metastasis of a
             solid tumour):

          -  Biphosphonates: ZOLEDRONATE (ZOMETA®), PAMIDRONATE (AREDIA®, OSTEPAM®)

          -  Anti-angiogenic: DENOSUMAB (XGEVA®), BEVACIZUMAB (AVASTIN®), RITUXIMAB (MABTHERA®,
             RIXATHON®, TRUXIMA®), SUNITINIB (SUTENT®), PAZOPANIB (VOTRIENT®), AXITINIB (INLYTA®),
             CARBOZANTINIB (CABOMETYX®, COMETRIQ®), SORAFENIB (NEXAVAR®)

          -  Patient who has had an oral surgical procedure (single or multiple dental extraction,
             with or without alveolectomy, under local or general anesthesia)

        Exclusion Criteria:

          -  History of oral and/or cervico-facial radiotherapy

          -  Patient treated successively with biphosphonates and then with anti-angiogenic drugs.

          -  Patient under guardianship, curatorship, or imprisonment

          -  Patient who has notified his refusal to participate in the research
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emeline Noaillon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Sud Francilien</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elodie Henry, CRU manager</last_name>
    <phone>+33161693730</phone>
    <email>elodie.henry@chsf.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Sud Francilien</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elodie Henry, CRU manager</last_name>
      <phone>+33161693730</phone>
      <email>elodie.henry@chsf.fr</email>
    </contact>
    <investigator>
      <last_name>Emeline Noaillon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Lemonier, DDS</last_name>
      <phone>+33149812111</phone>
      <email>nicolas.lemonier@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas Lemonier, DDS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Bretagne Atlantique</name>
      <address>
        <city>Vannes</city>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Pequignot, DDS</last_name>
      <phone>+33297014277</phone>
      <email>sophie.pequignot@ch-bretagne-atlantique.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie Pequignot, DDS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Jacques BRAU, MD</last_name>
      <phone>+331612734867</phone>
      <email>jean-jacques.brau@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7.</citation>
    <PMID>12966493</PMID>
  </results_reference>
  <results_reference>
    <citation>Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007 Mar;65(3):369-76.</citation>
    <PMID>17307580</PMID>
  </results_reference>
  <results_reference>
    <citation>Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56. doi: 10.1016/j.joms.2014.04.031. Epub 2014 May 5. Erratum in: J Oral Maxillofac Surg. 2015 Jul;73(7):1440. J Oral Maxillofac Surg. 2015 Sep;73(9):1879.</citation>
    <PMID>25234529</PMID>
  </results_reference>
  <results_reference>
    <citation>Qi WX, Tang LN, He AN, Yao Y, Shen Z. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol. 2014 Apr;19(2):403-10. doi: 10.1007/s10147-013-0561-6. Epub 2013 Apr 20.</citation>
    <PMID>23605142</PMID>
  </results_reference>
  <results_reference>
    <citation>Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg. 2009 May;67(5 Suppl):61-70. doi: 10.1016/j.joms.2009.01.007. Review.</citation>
    <PMID>19371816</PMID>
  </results_reference>
  <results_reference>
    <citation>Gaudin E, Seidel L, Bacevic M, Rompen E, Lambert F. Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis. J Clin Periodontol. 2015 Oct;42(10):922-32. doi: 10.1111/jcpe.12455. Epub 2015 Nov 3. Review.</citation>
    <PMID>26362756</PMID>
  </results_reference>
  <results_reference>
    <citation>Peddi P, Lopez-Olivo MA, Pratt GF, Suarez-Almazor ME. Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev. 2013 Feb;39(1):97-104. doi: 10.1016/j.ctrv.2012.07.002. Epub 2012 Aug 13. Review.</citation>
    <PMID>22898302</PMID>
  </results_reference>
  <results_reference>
    <citation>Landesberg R, Woo V, Cremers S, Cozin M, Marolt D, Vunjak-Novakovic G, Kousteni S, Raghavan S. Potential pathophysiological mechanisms in osteonecrosis of the jaw. Ann N Y Acad Sci. 2011 Feb;1218:62-79. doi: 10.1111/j.1749-6632.2010.05835.x. Review.</citation>
    <PMID>21291478</PMID>
  </results_reference>
  <results_reference>
    <citation>Reich W, Bilkenroth U, Schubert J, Wickenhauser C, Eckert AW. Surgical treatment of bisphosphonate-associated osteonecrosis: Prognostic score and long-term results. J Craniomaxillofac Surg. 2015 Nov;43(9):1809-22. doi: 10.1016/j.jcms.2015.07.035. Epub 2015 Aug 6.</citation>
    <PMID>26321065</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>jaw osteonecrosis</keyword>
  <keyword>biphosphonates</keyword>
  <keyword>antiangiogenic agents</keyword>
  <keyword>oral surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteonecrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

